Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer

CONCLUSION: PLR and NLR could be used to predict the efficacy of neoadjuvant therapy with the taxane, anthracycline, and lobaplatin regimen for patients with TNBC, as patients who had lower PLR and NLR values had a higher tpCR rate and a better long-term prognosis.PMID:38431781 | DOI:10.1093/oncolo/oyae025

Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Cheng Wang Qiyun Shi Guozhi Zhang Xiujuan Wu Wenting Yan Andi Wan Siyi Xiong Long Yuan Hao Tian Dandan Ma Jun Jiang Xiaowei Qi Yi Zhang Source Type: research